'Pharmaceutical anti-counterfeiting technologies market will reach $1.2bn in 2015' predicts Visiongain report

Press Release   •   Oct 29, 2012 12:17 GMT

That study predicts that the pharmaceutical anti-counterfeiting market will grow strongly from 2012 to 2022. The illicit trade in counterfeit drugs costs the pharmaceutical industry billions of dollars every year. Also, the consumption of counterfeit drugs poses a serious threat to public health. Visiongain believes drug counterfeiting is one of the most pressing challenges facing the pharmaceutical industry. The more-widespread use of anti-counterfeiting technologies will help to defeat counterfeiting activities. Many opportunities exist for pharma companies and technology suppliers from 2012 to 2022, the report shows.

Dr Peter Williamson, a pharmaceutical industry analyst in visiongain, said: “Growth of the market will be stimulated by the introduction of industry-wide standards. To achieve this, regulatory bodies will enforce mandatory supply chain track-and-trace technologies. Increasingly, drugs are being protected from counterfeiting using a range of innovative technologies. Leading pharma companies are now realising the serious threat of counterfeit medicines by working closely with anti-counterfeit organisations. Visiongain believes that RFID and 2D barcoding technologies will be key areas of industry and market growth. Consumer empowerment will also help in efforts to counter fake drugs, further benefiting the technology market for pharma supply chain security.

“The pharmaceutical anti-counterfeiting technologies market has great potential from 2012 to 2022. In addition, drug companies must maintain good reputations and act to protect their revenues. The key to supply chain security lies in the successful introduction of industry-wide standards worldwide. Cooperation and cohesion between regulatory authorities and manufacturers must improve. Also, increasing public awareness will help the fight against drug counterfeiters, benefiting suppliers of the technology, pharma companies and other stakeholders.”

Visiongain’s report shows revenue forecasts to 2022 at world market, technology submarket, and national level. It forecasts world sales for the following commercial segments:

• Security printing
• RFID (radio frequency identification)
• Taggants
• Holograms/OVD (optical variable devices)
• Other pharma anti-counterfeiting technologies.

That new investigation gives profiles of 17 leading companies, including 3M, Authentix, Colorcon, NanoGuardian and Thermo Scientific. It also shows interviews with two companies.

The analysis assesses trends and commercial outlooks worldwide. It also forecasts revenues for leading national markets. Countries and regions analysed are the US, Japan, EU5 countries (as a group), Brazil, Russia, India and China.

Pharmaceutical Anti-counterfeiting Technologies: Market Analysis 2012-2022 adds to visiongain’s range of analytical reports on industries and markets in healthcare.

For sample pages and further information concerning the Visiongain report Pharmaceutical Anti-counterfeiting Technologies: Market Analysis 2012-2022 please visit

For an executive summary please contact:
Email: Sara Peerun on
Tel: +44 (0) 20 7336 6100

Notes for Editors
If you are interested in a more detailed overview of this report, please send an e-mail to or call her on +44 (0) 207 336 6100

About visiongain

Visiongain is one of the fastest growing and most innovative independent media companies in Europe. Based in London, UK, visiongain produces a host of business-2-business conferences, newsletters, management reports and e-zines focusing on the Energy, Telecoms, Pharmaceutical, Defence, Aviation and Materials sectors.

Visiongain publishes reports produced by its in-house analysts, who are qualified experts in their field. Visiongain has firmly established itself as the first port-of-call for the business professional, who needs independent, high quality, original material to rely and depend on.